JP2023526451A5 - - Google Patents
Info
- Publication number
- JP2023526451A5 JP2023526451A5 JP2022570573A JP2022570573A JP2023526451A5 JP 2023526451 A5 JP2023526451 A5 JP 2023526451A5 JP 2022570573 A JP2022570573 A JP 2022570573A JP 2022570573 A JP2022570573 A JP 2022570573A JP 2023526451 A5 JP2023526451 A5 JP 2023526451A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- pharmaceutically acceptable
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027536P | 2020-05-20 | 2020-05-20 | |
| US63/027,536 | 2020-05-20 | ||
| PCT/GB2021/051220 WO2021234391A1 (en) | 2020-05-20 | 2021-05-20 | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526451A JP2023526451A (ja) | 2023-06-21 |
| JP2023526451A5 true JP2023526451A5 (enExample) | 2024-05-22 |
Family
ID=76532225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570573A Pending JP2023526451A (ja) | 2020-05-20 | 2021-05-20 | ネクチン－４に特異的な二環式ペプチドリガンド及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181749A1 (enExample) |
| EP (1) | EP4153240A1 (enExample) |
| JP (1) | JP2023526451A (enExample) |
| KR (1) | KR20230037502A (enExample) |
| CN (1) | CN115697417A (enExample) |
| AU (1) | AU2021276616A1 (enExample) |
| CA (1) | CA3179152A1 (enExample) |
| IL (1) | IL298382A (enExample) |
| MX (1) | MX2022014550A (enExample) |
| WO (1) | WO2021234391A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| EP4719481A1 (en) * | 2023-06-01 | 2026-04-08 | BicycleTx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| WO2024248859A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| CN117003830A (zh) * | 2023-08-04 | 2023-11-07 | 湖南中晟全肽生化有限公司 | 靶向Nectin-4的多肽及其用途 |
| EP4777136A1 (en) * | 2023-09-13 | 2026-07-22 | BicycleTx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ267796A3 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
| US8329188B2 (en) * | 2008-11-12 | 2012-12-11 | Theraclone Sciences, Inc. | Human M2e peptide immunogens |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| JP2018503595A (ja) * | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| EP3677589B1 (en) * | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| TWI825046B (zh) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| WO2020178574A1 (en) * | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| MX2021012994A (es) * | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| KR20230060509A (ko) * | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | 넥틴-4 항체 및 이의 용도 |
-
2021
- 2021-05-20 AU AU2021276616A patent/AU2021276616A1/en active Pending
- 2021-05-20 KR KR1020227044522A patent/KR20230037502A/ko active Pending
- 2021-05-20 MX MX2022014550A patent/MX2022014550A/es unknown
- 2021-05-20 US US17/926,454 patent/US20230181749A1/en active Pending
- 2021-05-20 JP JP2022570573A patent/JP2023526451A/ja active Pending
- 2021-05-20 EP EP21733852.4A patent/EP4153240A1/en active Pending
- 2021-05-20 CA CA3179152A patent/CA3179152A1/en active Pending
- 2021-05-20 CN CN202180043142.4A patent/CN115697417A/zh active Pending
- 2021-05-20 IL IL298382A patent/IL298382A/en unknown
- 2021-05-20 WO PCT/GB2021/051220 patent/WO2021234391A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505756A5 (enExample) | ||
| JP2024543505A5 (enExample) | ||
| Jiang et al. | A natural drug entry channel in the ferritin nanocage | |
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| JP2018528184A5 (enExample) | ||
| WO2007095850A1 (en) | A pharmaceutical composition of docetaxel, preparation and use | |
| JP2013500947A5 (enExample) | ||
| JP2010531877A5 (enExample) | ||
| JP2022527334A5 (enExample) | ||
| CN112826939A (zh) | 一种腹腔灌注纳米药物及其制备方法与应用 | |
| CN101909613A (zh) | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 | |
| WO2008119260A1 (en) | A medicinal composition of carmustine, preparation method and application | |
| KR101100786B1 (ko) | 암에 대한 방사선 치료 증진용 조성물 | |
| JP2024521578A5 (enExample) | ||
| WO2017133706A1 (zh) | 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用 | |
| JP2021511344A5 (enExample) | ||
| JP2024511354A5 (enExample) | ||
| AU2016337370A1 (en) | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C | |
| US20260021106A1 (en) | Combination therapy for treating cancers | |
| Inohara et al. | Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study | |
| US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
| CN113993515B (zh) | 使用藏红花酸治疗实体肿瘤的方法 | |
| US20260027126A1 (en) | Combination therapy for treating cancers | |
| US7863255B2 (en) | Methods of administering antitumor agent comprising deoxycytidine derivative | |
| CN110025617A (zh) | 双去甲基汉防己甲素双甲酸乙酯与酪氨酸激酶抑制剂的药物组合物 |